Article Figures & Data
Figures
- Figure 1 Median lymphocyte counts in patients treated with alemtuzumab 12 mg
Median total lymphocyte, CD4+ and CD8+ T-lymphocyte, and CD19+ B-lymphocyte counts in the overall pooled Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis population treated with alemtuzumab 12 mg. N value range over 24 months: 752–802 patients. Vertical lines indicate administration of alemtuzumab. Dashed horizontal lines represent LLN for each of the lymphocyte subsets presented. IQR = interquartile range; LLN = lower limit of normal.
- Figure 2 Median lymphocyte counts in alemtuzumab-treated patients with or without autoimmune AEs
(A) Median total lymphocyte, (B) CD4+ and (C) CD8+ T-lymphocyte, and (D) CD19+ B-lymphocyte counts in patients from the pooled Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis trials treated with alemtuzumab 12 mg, stratified by the presence or absence of autoimmune events. N value range over 24 months: 415–447 patients without autoimmune AEs; 337–355 patients with autoimmune AEs. Vertical lines indicate administration of alemtuzumab. AE = adverse event; IQR = interquartile range; LLN = lower limit of normal.
- Figure 3 Median lymphocyte counts in alemtuzumab-treated patients with or without disease activity
Median total lymphocyte, CD4+ and CD8+ T-lymphocyte, and CD19+ B-lymphocyte counts in Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis patients treated with alemtuzumab 12 mg, stratified by the presence or absence of (A) relapse, (B) 6-month CDW, and (C) MRI disease activity. N value range over 24 months: 356–388 patients without relapse; 395–414 patients with relapse; 567–606 patients without CDW; 184–196 patients with CDW; 263–280 patients without MRI activity; 485–516 patients with MRI activity. Vertical lines indicate administration of alemtuzumab. CDW = confirmed disability worsening; IQR = interquartile range; LLN = lower limit of normal.
- Figure 4 Lymphocyte subset counts in alemtuzumab-treated patients with or without autoimmune AEs or disease activity
(A) CD4+ T-, (B) CD8+ T-, and (C) CD19+ B-lymphocyte subset counts in Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis patients treated with alemtuzumab 12 mg, stratified by the presence or absence of autoimmune AEs, relapse, 6-month CDW, and MRI disease activity. N value range over 24 months: 29–72 patients without autoimmune AEs; 30–76 patients with autoimmune AEs; 23–72 patients without relapse; 27–75 patients with relapse; 44–108 patients without CDW; 14–38 patients with CDW; 23–63 patients without MRI activity; 35–84 patients with MRI activity. AE = adverse event; CDW = confirmed disability worsening; IQR = interquartile range; Treg = regulatory T.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg